Tags

Type your tag names separated by a space and hit enter

The efficacy of Femal in women with premenstrual syndrome: a randomised, double-blind, parallel-group, placebo-controlled, multicentre study.
Adv Ther. 2008 Jun; 25(6):595-607.AT

Abstract

INTRODUCTION

A double-blind, placebo-controlled, randomised, parallel-group, multicentre study was conducted to evaluate the effect of a pollen-based herbal medicinal product, Femal (Sea-Band Ltd, Leicestershire, UK), on premenstrual sleep disturbances (PSD) in women with premenstrual syndrome (PMS).

METHODS

Femal, 160 mg twice-daily, was given for four menstrual cycles to 50 women, and placebo to 51 women. PSD were evaluated on a visual analogue scale prior to and after the four cycles. The effect on overall PMS symptoms was assessed with the Steiner premenstrual tension syndrome (PMTS) self-rating questionnaire. The results were analysed statistically based on intention to treat.

RESULTS

Femal treatment resulted in a significant reduction in PSD (P<0.05) whereas placebo had no significant effect (P>0.05). In a subgroup analysis of women with irritability as their main PMS symptom cluster, the reduction of PSD was even more pronounced (P<0.001). There was no significant difference in overall degree of PMS symptom reduction between Femal and placebo when all participating women were evaluated (P>0.05). However, in women with irritability as their main PMS symptom cluster, Femal treatment resulted in a significant reduction of the Steiner score (P<0.05). The frequency of adverse events was not significantly different in women on Femal compared to women on placebo (P>0.05). No serious adverse events were recorded.

CONCLUSION

Femal treatment reduced PSD to a significant degree, particularly in women with irritability as their main PMS symptom. Femal treatment also reduced overall PMS symptoms in women with irritability (but not dysphoria) as their main PMS symptom. The safety of Femal and its efficacy in PSD and other symptoms in women with irritability as the main symptom cluster makes this herbal medicinal product a promising addition to the therapeutic arsenal for women with PMS.

Authors+Show Affiliations

Greverud Legesenter, Flåtestadveien 3, 1415, Oppegård, Norway. gerhardt.gerhardsen@gmail.comNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Multicenter Study
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

18568441

Citation

Gerhardsen, Gerhard, et al. "The Efficacy of Femal in Women With Premenstrual Syndrome: a Randomised, Double-blind, Parallel-group, Placebo-controlled, Multicentre Study." Advances in Therapy, vol. 25, no. 6, 2008, pp. 595-607.
Gerhardsen G, Hansen AV, Killi M, et al. The efficacy of Femal in women with premenstrual syndrome: a randomised, double-blind, parallel-group, placebo-controlled, multicentre study. Adv Ther. 2008;25(6):595-607.
Gerhardsen, G., Hansen, A. V., Killi, M., Fornitz, G. G., Pedersen, F., & Roos, S. B. (2008). The efficacy of Femal in women with premenstrual syndrome: a randomised, double-blind, parallel-group, placebo-controlled, multicentre study. Advances in Therapy, 25(6), 595-607. https://doi.org/10.1007/s12325-008-0072-4
Gerhardsen G, et al. The Efficacy of Femal in Women With Premenstrual Syndrome: a Randomised, Double-blind, Parallel-group, Placebo-controlled, Multicentre Study. Adv Ther. 2008;25(6):595-607. PubMed PMID: 18568441.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - The efficacy of Femal in women with premenstrual syndrome: a randomised, double-blind, parallel-group, placebo-controlled, multicentre study. AU - Gerhardsen,Gerhard, AU - Hansen,Anne V, AU - Killi,Marianne, AU - Fornitz,Gitte Gleerup, AU - Pedersen,Frank, AU - Roos,Signe Barfod, PY - 2008/6/24/pubmed PY - 2009/1/7/medline PY - 2008/6/24/entrez SP - 595 EP - 607 JF - Advances in therapy JO - Adv Ther VL - 25 IS - 6 N2 - INTRODUCTION: A double-blind, placebo-controlled, randomised, parallel-group, multicentre study was conducted to evaluate the effect of a pollen-based herbal medicinal product, Femal (Sea-Band Ltd, Leicestershire, UK), on premenstrual sleep disturbances (PSD) in women with premenstrual syndrome (PMS). METHODS: Femal, 160 mg twice-daily, was given for four menstrual cycles to 50 women, and placebo to 51 women. PSD were evaluated on a visual analogue scale prior to and after the four cycles. The effect on overall PMS symptoms was assessed with the Steiner premenstrual tension syndrome (PMTS) self-rating questionnaire. The results were analysed statistically based on intention to treat. RESULTS: Femal treatment resulted in a significant reduction in PSD (P<0.05) whereas placebo had no significant effect (P>0.05). In a subgroup analysis of women with irritability as their main PMS symptom cluster, the reduction of PSD was even more pronounced (P<0.001). There was no significant difference in overall degree of PMS symptom reduction between Femal and placebo when all participating women were evaluated (P>0.05). However, in women with irritability as their main PMS symptom cluster, Femal treatment resulted in a significant reduction of the Steiner score (P<0.05). The frequency of adverse events was not significantly different in women on Femal compared to women on placebo (P>0.05). No serious adverse events were recorded. CONCLUSION: Femal treatment reduced PSD to a significant degree, particularly in women with irritability as their main PMS symptom. Femal treatment also reduced overall PMS symptoms in women with irritability (but not dysphoria) as their main PMS symptom. The safety of Femal and its efficacy in PSD and other symptoms in women with irritability as the main symptom cluster makes this herbal medicinal product a promising addition to the therapeutic arsenal for women with PMS. SN - 0741-238X UR - https://www.unboundmedicine.com/medline/citation/18568441/The_efficacy_of_Femal_in_women_with_premenstrual_syndrome:_a_randomised_double_blind_parallel_group_placebo_controlled_multicentre_study_ L2 - https://dx.doi.org/10.1007/s12325-008-0072-4 DB - PRIME DP - Unbound Medicine ER -